<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475085</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000544841</org_study_id>
    <secondary_id>U10CA037420</secondary_id>
    <secondary_id>URCC-U1105</secondary_id>
    <nct_id>NCT00475085</nct_id>
  </id_info>
  <brief_title>Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial</brief_title>
  <official_title>Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Roscoe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine,
      aprepitant, and palonosetron, may help lessen or prevent nausea. It is not yet known which
      combination of antiemetic drugs is more effective in preventing nausea caused by
      chemotherapy.

      PURPOSE: This randomized phase III trial is comparing different combinations of granisetron,
      dexamethasone, prochlorperazine, aprepitant, and palonosetron to see how well they work in
      preventing nausea in patients undergoing chemotherapy for breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy of palonosetron hydrochloride and dexamethasone followed by
           prochlorperazine with vs without dexamethasone in preventing delayed nausea in women
           with chemotherapy-naive breast cancer. (Arms I and IV)

        -  Determine if palonosetron hydrochloride is more effective than granisetron hydrochloride
           in controlling treatment-related delayed nausea in these patients. (Arms I and II)

        -  Determine if the currently recommended antiemetic guideline of aprepitant combined with
           palonosetron hydrochloride and dexamethasone is the most effective antiemetic regimen
           for controlling treatment-related delayed nausea in these patients. (Arms III and IV)

      Secondary

        -  Determine if the addition of dexamethasone to prochlorperazine is more effective than
           the same regimen without dexamethasone for reducing interference with functioning caused
           by chemotherapy-induced nausea and vomiting in these patients. (Arms I and IV)

        -  Determine if palonosetron hydrochloride is more effective than granisetron hydrochloride
           for reducing interference with functioning caused by chemotherapy-induced nausea and
           vomiting in these patients. (Arms I and II)

        -  Determine if the currently recommended antiemetic guideline of aprepitant combined with
           palonosetron hydrochloride and dexamethasone is the most effective antiemetic regimen
           for reducing interference with functioning due to chemotherapy-induced nausea and
           vomiting in these patients. (Arms III and IV)

      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
      are stratified according to CCOP center and gender. Patients are randomized to 1 of 4
      treatment arms. Patients receive study treatment approximately 30 minutes before their
      scheduled first chemotherapy treatment.

        -  Arm I: Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral
           placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo
           once daily on days 2 and 3.

        -  Arm II: Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral
           placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo
           once daily on days 2 and 3.

        -  Arm III: Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day
           1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral
           placebo twice daily on days 2 and 3.

        -  Arm IV: Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral
           placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone
           once daily on days 2 and 3.

      Quality of life is assessed at baseline and on day 4. Nausea and vomiting, fatigue, sleep
      quality, exercise, and the need for rescue medication (metoclopramide) are assessed on days
      1-4.

      PROJECTED ACCRUAL: A total of 890 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Home Record: Severity of Delayed Nausea</measure>
    <time_frame>average of day 1 afternoon, evening and night, and all of days 2 and 3</time_frame>
    <description>1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1021</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Arm III</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granisetron hydrochloride</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Kytril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron hydrochloride</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prochlorperazine</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Compazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Have a diagnosis of cancer and be chemotherapy naive.

          -  Must be scheduled to receive a chemotherapy treatment containing doxorubicin
             hydrochloride, epirubicin hydrochloride, cisplatin, carboplatin, or oxaliplatin (any
             dose or schedule) without concurrent radiotherapy or interferon treatment

          -  Chemotherapy may be for adjuvant, neoadjuvant, curative or palliative intent.

          -  Dose-dense regimens (e.g. chemotherapy with doxorubicin or epirubicin given every two
             weeks)are allowed.

          -  For the purposes of this study, Day 1 of chemotherapy will be defined as the day of
             administration of cisplatin, carboplatin, oxaliplatin, doxorubicin or epirubicin.

          -  Regimens with multiple-day doses of doxorubicin, epirubicin, cisplatin, carboplatin,
             oxaliplatin, dacarbazine, hexamethylmelamine, nitrosoureas, or streptozocin are not
             allowed. Chemotherapy agents, other than those listed above, may be given orally,
             intravenously, or by continuous infusion on one or multiple days.

          -  Able to understand English

        Exclusion criteria:

          -  No symptomatic brain metastases

          -  No concurrent or impending bowel obstruction

          -  Regimens containing liposomal doxorubicin or cisplatin are not allowed.

          -  No concurrent pimozide, terfenadine, astemizole, or cisapride

          -  No concurrent doxorubicin hydrochloride liposome or cisplatin

          -  No concurrent multiple-day doses of dacarbazine, altretamine, nitrosoureas,
             streptozocin, cisplatin, carboplatin, or oxaliplatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A. Roscoe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MBCCOP - Gulf Coast</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Hematology-Oncology Associates of Central New York</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - North Shore University Hospital</name>
      <address>
        <city>Manhassett</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-0986</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>July 12, 2013</results_first_submitted>
  <results_first_submitted_qc>October 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2013</results_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester NCORP Research Base</investigator_affiliation>
    <investigator_full_name>Joseph Roscoe</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients from 15 private-practice oncology groups in the USA affiliated with the University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP)were enrolled by research personnel from May 2007 to September 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 Palonosetron, Dexamethasone, Compazine</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 Granisetron, Dexamethasone, Compazine</title>
          <description>Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
granisetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 Aprepitant, Palonosetron, Dexamethasone</title>
          <description>Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
placebo : Given orally
aprepitant : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="P4">
          <title>Arm 4 Palonosetron, Dexamethasone, Compazine, Dexamethasone</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="260"/>
                <participants group_id="P4" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="234"/>
                <participants group_id="P3" count="241"/>
                <participants group_id="P4" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm II</title>
          <description>Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
granisetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="B2">
          <title>Arm III</title>
          <description>Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
placebo : Given orally
aprepitant : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="B3">
          <title>Arm I</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="B4">
          <title>Arm IV</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
            <count group_id="B2" value="260"/>
            <count group_id="B3" value="254"/>
            <count group_id="B4" value="253"/>
            <count group_id="B5" value="1021"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="12.7"/>
                    <measurement group_id="B2" value="58.6" spread="11.4"/>
                    <measurement group_id="B3" value="57.1" spread="12.4"/>
                    <measurement group_id="B4" value="58.2" spread="11.4"/>
                    <measurement group_id="B5" value="57.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="208"/>
                    <measurement group_id="B5" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="229"/>
                    <measurement group_id="B5" value="918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="253"/>
                    <measurement group_id="B5" value="1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="198"/>
                    <measurement group_id="B5" value="781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Radiotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Home Record: Severity of Delayed Nausea</title>
        <description>1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse</description>
        <time_frame>average of day 1 afternoon, evening and night, and all of days 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II</title>
            <description>Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
granisetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
          </group>
          <group group_id="O2">
            <title>Arm III</title>
            <description>Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
placebo : Given orally
aprepitant : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
          </group>
          <group group_id="O3">
            <title>Arm I</title>
            <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
          </group>
          <group group_id="O4">
            <title>Arm IV</title>
            <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
          </group>
        </group_list>
        <measure>
          <title>Home Record: Severity of Delayed Nausea</title>
          <description>1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.27"/>
                    <measurement group_id="O2" value="1.65" spread="1.15"/>
                    <measurement group_id="O3" value="1.87" spread="1.20"/>
                    <measurement group_id="O4" value="1.68" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Group 1 - Group 2 (palonosetron vs. granisetron)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.718</p_value>
            <p_value_desc>Response skewed. P-value determined after Box-Cox transformation (lambda=-1.6). Significance level set to 0.017 to account for three tested hypotheses.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Testing and estimation performed using contrasts in the context of an omnibus ANOVA.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.225</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Group 1 - Group 4 (adding dexamethasone)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Response skewed. P-value determined after Box-Cox transformation (lambda=-1.6). Significance level set to 0.017 to account for three tested hypotheses.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Testing and estimation performed using contrasts in the context of an omnibus ANOVA.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.195</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.407</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Group 3 - Group 4 (aprepitant vs. prochlorperazine)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <p_value_desc>Response skewed. P-value determined after Box-Cox transformation (lambda=-1.6). Significance level set to 0.017 to account for three tested hypotheses.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Testing and estimation performed using contrasts in the context of an omnibus ANOVA.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.236</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm II</title>
          <description>Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
granisetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="E2">
          <title>Arm III</title>
          <description>Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
placebo : Given orally
aprepitant : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="E3">
          <title>Arm I</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
        <group group_id="E4">
          <title>Arm IV</title>
          <description>Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
placebo : Given orally
prochlorperazine : Given orally or IV
palonosetron hydrochloride : Given orally or IV
dexamethasone : Given orally or IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="17"/>
                <counts group_id="E3" subjects_affected="16"/>
                <counts group_id="E4" subjects_affected="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Trombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Restless</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>MRSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Charles Heckler</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585 273-1141</phone>
      <email>checkler@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

